Eva Carrasco
Overview
Explore the profile of Eva Carrasco including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1612
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martin M, Carrasco E, Rodriguez-Lescure A, Andres R, Servitja S, Anton A, et al.
Breast Cancer Res Treat
. 2023 Jun;
201(2):151-159.
PMID: 37338729
Purpose: The monarchE trial showed that the addition of abemaciclib improves efficacy in patients with high-risk early breast cancer (EBC). We analyzed the long-term outcomes of a population similar to...
2.
Perez-Fidalgo J, Criscitiello C, Carrasco E, Regan M, Di Leo A, Ribi K, et al.
Future Oncol
. 2022 Apr;
18(19):2339-2349.
PMID: 35465733
ALPHABET is a randomized phase III trial assessing alpelisib + trastuzumab with or without fulvestrant in previously treated HER2-positive -mutated advanced breast cancer. Patients will be included in two cohorts...
3.
Martin M, Zielinski C, Ruiz-Borrego M, Carrasco E, Ciruelos E, Munoz M, et al.
Eur J Cancer
. 2022 Apr;
168:12-24.
PMID: 35429901
Background: An earlier analysis of the PEARL phase III study showed that palbociclib plus endocrine therapy (ET) does not improve progression-free survival (PFS) over capecitabine in aromatase inhibitor-resistant, hormone receptor-positive/human...
4.
Garcia-Saenz J, Martinez-Janez N, Cubedo R, Jerez Y, Lahuerta A, Gonzalez-Santiago S, et al.
Clin Cancer Res
. 2022 Jan;
28(6):1107-1116.
PMID: 34980598
Purpose: This phase II study investigated daily or weekly sapanisertib (a selective dual inhibitor of mTOR complexes 1 and 2) in combination with fulvestrant. Patients And Methods: Postmenopausal women with...
5.
Kahan Z, Gil-Gil M, Ruiz-Borrego M, Carrasco E, Ciruelos E, Munoz M, et al.
Eur J Cancer
. 2021 Aug;
156:70-82.
PMID: 34425406
Background: The PEARL study showed that palbociclib plus endocrine therapy (palbociclib/ET) was not superior to capecitabine in improving progression-free survival in postmenopausal patients with metastatic breast cancer resistant to aromatase...
6.
Ciruelos E, Montano A, Rodriguez C, Gonzalez-Flores E, Lluch A, Garrigos L, et al.
Eur J Cancer Care (Engl)
. 2020 Jun;
29(4):e13253.
PMID: 32578279
Objective: We compared patients' preferences for intravenous (IV-t) versus subcutaneous (SC-t) trastuzumab administration. Methods: Phase III, open-label, multicentre study in HER2-positive metastatic breast cancer. Patients were receiving IV-t for at...
7.
Lluch A, Barrios C, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, et al.
J Clin Oncol
. 2019 Dec;
38(3):203-213.
PMID: 31804894
Purpose: Operable triple-negative breast cancers (TNBCs) have a higher risk of relapse than non-TNBCs with standard therapy. The GEICAM/2003-11_CIBOMA/2004-01 trial explored extended adjuvant capecitabine after completion of standard chemotherapy in...
8.
Lluch A, Gonzalez-Angulo A, Casadevall D, Eterovic A, Martinez de Duenas E, Zheng X, et al.
Eur J Cancer
. 2019 Sep;
120:54-64.
PMID: 31491604
Background: Changes in the clinical subtype (CS) and intrinsic subtype (IS) between breast cancer (BC) metastases and corresponding primary tumours have been reported. However, their relationship with tumour genomic changes...
9.
Ruiz-Borrego M, Guerrero-Zotano A, Bermejo B, Ramos M, Cruz J, Baena-Canada J, et al.
Breast Cancer Res Treat
. 2019 Jun;
177(1):115-125.
PMID: 31152327
Purpose: GEICAM/2006-10 compared anastrozole (A) versus fulvestrant plus anastrozole (A + F) to test the hypothesis of whether a complete oestrogen blockade is superior to aromatase inhibitors alone in breast...
10.
Lope V, Martin M, Castello A, Ruiz A, Casas A, Baena-Canada J, et al.
Sci Rep
. 2019 Mar;
9(1):3904.
PMID: 30846706
This study analyzes the association of excessive energy intake and caloric restriction with breast cancer (BC) risk taking into account the individual energy needs of Spanish women. We conducted a...